tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GMAB Stock Latest News

Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
Company AnnouncementsGenmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
7d ago
BNTX
GMAB
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment
PremiumCompany Announcements
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment
7d ago
GMAB
Genmab’s Phase 3 Study on Rina-S: A Potential Game-Changer for Ovarian Cancer Treatment
PremiumCompany Announcements
Genmab’s Phase 3 Study on Rina-S: A Potential Game-Changer for Ovarian Cancer Treatment
7d ago
GMAB
Genmab’s GEN1057 Trial: A New Hope in Cancer Treatment?
PremiumCompany Announcements
Genmab’s GEN1057 Trial: A New Hope in Cancer Treatment?
7d ago
GMAB
Pfizer and Genmab’s Tivdak Study: Ocular Side Effects Under the Microscope
PremiumCompany Announcements
Pfizer and Genmab’s Tivdak Study: Ocular Side Effects Under the Microscope
7d ago
PFE
GMAB
Genmab’s GEN1286 Study: A Potential Game-Changer in Cancer Treatment?
PremiumCompany AnnouncementsGenmab’s GEN1286 Study: A Potential Game-Changer in Cancer Treatment?
7d ago
GMAB
Genmab’s Rina-S Study: A New Hope for Advanced Solid Tumors
Premium
Company Announcements
Genmab’s Rina-S Study: A New Hope for Advanced Solid Tumors
7d ago
GMAB
Genmab’s Phase 3 Trial: A Potential Game-Changer in NSCLC Treatment
Premium
Company Announcements
Genmab’s Phase 3 Trial: A Potential Game-Changer in NSCLC Treatment
7d ago
GMAB
Genmab’s Promising Melanoma Study: A Potential Game-Changer for Investors
PremiumCompany Announcements
Genmab’s Promising Melanoma Study: A Potential Game-Changer for Investors
7d ago
GMAB
Genmab’s GEN1160 Study: A Potential Game-Changer in Cancer Treatment?
PremiumCompany Announcements
Genmab’s GEN1160 Study: A Potential Game-Changer in Cancer Treatment?
7d ago
GMAB
Genmab’s Promising Colorectal Cancer Treatment Drives Buy Rating
PremiumRatings
Genmab’s Promising Colorectal Cancer Treatment Drives Buy Rating
8d ago
GMAB
Promising Clinical Developments in Genmab’s Portfolio Reinforce Buy Rating
PremiumRatings
Promising Clinical Developments in Genmab’s Portfolio Reinforce Buy Rating
14d ago
GMAB
Genmab falls -6.5%
PremiumThe FlyGenmab falls -6.5%
15d ago
GMAB
Genmab’s Oncology Advancements and Strategic Positioning Drive Buy Rating
Premium
Ratings
Genmab’s Oncology Advancements and Strategic Positioning Drive Buy Rating
15d ago
GMAB
Genmab announces new data from Phase 1/2 RAINFOL-01 trial
Premium
The Fly
Genmab announces new data from Phase 1/2 RAINFOL-01 trial
16d ago
GMAB
Genmab Reports Strong Q3 2025 DARZALEX® Sales
PremiumCompany Announcements
Genmab Reports Strong Q3 2025 DARZALEX® Sales
18d ago
6K
GMAB
Genmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
PremiumRatings
Genmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
20d ago
GMAB
Genmab reports net sales of Darzalex for Q3 2025 of $3.67B
PremiumThe Fly
Genmab reports net sales of Darzalex for Q3 2025 of $3.67B
21d ago
GMAB
Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
PremiumRatings
Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
25d ago
GMAB
Genmab price target raised to DKK 2,000 from DKK 1,900 at Deutsche Bank
PremiumThe FlyGenmab price target raised to DKK 2,000 from DKK 1,900 at Deutsche Bank
28d ago
GMAB
Genmab price target raised to $49 from $46 at Truist
Premium
The Fly
Genmab price target raised to $49 from $46 at Truist
29d ago
GMAB
MRUS
Genmab price target raised to $40 from $36 at H.C. Wainwright
Premium
The Fly
Genmab price target raised to $40 from $36 at H.C. Wainwright
1M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >